Pharmasyntez is actively developing, mastering production and bringing to the market innovative drugs. Annual participation in the Forum allows the company to attract projects at different stages of drug development: from the initial Drug Discovery/Drug Development phases to production and launching to the market.

Mikhail Shurygin, R&D Director of Pharmasyntez JSC, presented a report “Expectations from investments in the early stages of drug developments. Bridging the distance between science and production” in Bioinformatics section.

During the presentation, he noted that organizational aspects, in addition to issues of production technologies, play an important role in promoting early developments.

After the stages of scientific research and development, 99% of solutions are recognized as unpromising by pharmaceutical companies for further development based on the analysis of results, quality of research performed and patent protection.

“Making a perfect medicine is almost a utopia. To increase the investment potential of drug developments in early stages, it is necessary to involve the pharmaceutical manufacturer as early as possible. Also, the development team should include technologists and regulatory specialists. In addition, at the early stages of development it is already possible to use the capabilities of an industrial partner. And the absence of publication and public activity would be perfect for the manufacturer, at least until the filing of the application under the patent cooperation agreement, preferably until the stage of transition to clinical trials. These measures would create an environment in which the development process can be completed more successfully”.